Awaiting development: Guidance and quality standards

Showing 11 to 20 of 302

Guidance and quality standards awaiting development
Title	Type
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]	Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]	Technology appraisal guidance
Apraglutide for treating short bowel syndrome [ID6533]	Technology appraisal guidance
Aprocitentan for treating resistant hypertension [TSID10395]	Technology appraisal guidance
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]	Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]	Technology appraisal guidance
Atrasentan for treating primary IgA nephropathy [ID6588]	Technology appraisal guidance
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]	Technology appraisal guidance
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [TSID12189]	Technology appraisal guidance